PMID- 10880848
OWN - NLM
STAT- MEDLINE
DCOM- 20000830
LR  - 20190921
IS  - 0169-5002 (Print)
IS  - 0169-5002 (Linking)
VI  - 29
IP  - 1
DP  - 2000 Jul
TI  - The potential role of amifostine in the treatment of non small cell lung cancer.
PG  - 57-66
AB  - Amifostine protects healthy tissues but not tumor cells from the damage induced 
      by cytotoxic treatments, particularly ionizing radiations, alkylating and 
      platinating agents. The clinical effectiveness of amifostine has been 
      demonstrated by randomized trials in ovarian and head-and-neck cancer patients 
      treated with chemotherapy with or without radiation therapy. The available 
      pharmacoeconomic data confirm a favorable cost/utility ratio. The majority of non 
      small cell lung cancer (NSCLC) patients receive radio and/or chemotherapy. A role 
      for amifostine in these patients has been hypothesized, and some experiences 
      performed. The aim of this paper is to outline the present role of amifostine in 
      the treatment of NSCLC.
FAU - Castiglione, F
AU  - Castiglione F
AD  - Medical Oncology Service, Civic Hospital, Alba, Italy. castiglione@dada.it
FAU - Porcile, G
AU  - Porcile G
FAU - Gridelli, C
AU  - Gridelli C
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Radiation-Protective Agents)
RN  - M487QF2F4V (Amifostine)
SB  - IM
MH  - Amifostine/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/*radiotherapy
MH  - Combined Modality Therapy
MH  - Humans
MH  - Lung Neoplasms/drug therapy/*radiotherapy
MH  - Radiation-Protective Agents/*therapeutic use
RF  - 59
EDAT- 2000/07/06 11:00
MHDA- 2000/09/02 11:01
CRDT- 2000/07/06 11:00
PHST- 2000/07/06 11:00 [pubmed]
PHST- 2000/09/02 11:01 [medline]
PHST- 2000/07/06 11:00 [entrez]
AID - S0169-5002(00)00100-8 [pii]
AID - 10.1016/s0169-5002(00)00100-8 [doi]
PST - ppublish
SO  - Lung Cancer. 2000 Jul;29(1):57-66. doi: 10.1016/s0169-5002(00)00100-8.